National Cooperative Growth Study in CKD
Completed
- Conditions
- Growth Hormone Deficiency
- Registration Number
- NCT00616278
- Lead Sponsor
- University of California, Davis
- Brief Summary
The purpose of this study is to learn whether growth hormone being administered to children with Chronic Kidney Disease is effective and if it has any side effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
- Must be a patient of the UC Davis Medical Center pediatric clinic with Chronic Kidney Disease
Exclusion Criteria
- Greater than 18 years old
- Not a patient at the UC Davis Medical Center pediatric clinic
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome measures of the NCGS are ongoing safety and efficacy of Genentech GH preparations in pediatric growth disorders for which GH is initiated. per the study, the pt will be on GH treatement until the physician instructs them to stop
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie growth hormone therapy efficacy in pediatric CKD patients?
How does recombinant human growth hormone compare to standard-of-care in treating growth failure in ESRD?
Which biomarkers predict response to growth hormone in children with chronic renal insufficiency?
What adverse events are associated with long-term growth hormone use in CKD patients?
Are there combination therapies that enhance growth outcomes in pediatric renal disease?
Trial Locations
- Locations (1)
UC Davis Medical Center
🇺🇸Sacramento, California, United States
UC Davis Medical Center🇺🇸Sacramento, California, United States